Group 1 - The core point of the article is that Baike Biotechnology announced the resignation of Sun Wanfeng from his position as employee representative director and vice president, while he will continue to serve as assistant to the chairman [1] - Baike Biotechnology's revenue composition for the year 2024 is entirely from biopharmaceuticals, accounting for 100.0% [1] - As of the report, Baike Biotechnology has a market capitalization of 9.2 billion yuan [1]

中信证券股份有限公司 关于长春百克生物科技股份公司 将部分暂时闲置募集资金以定期存款方式存放的核查意见 根据《证券发行上市保荐业务管理办法》《上市公司募集资金监管规则》《上海 证券交易所科创板上市公司自律监管指引第1号——规范运作》《上海证券交易所科创 板股票上市规则》《科创板上市公司持续监管办法（试行）》等有关规定，作为长春 百克生物科技股份公司（以下简称"百克生物"或"公司"）首次公开发行股票并上市的 保荐机构，中信证券股份有限公司（以下简称"中信证券"）对百克生物将部分暂时闲 置募集资金以定期存款方式存放的事项进行了核查，具体如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意长春百克生物科技股份公司首次公开发行 股票注册的批复》（证监许可[2021]1594号）的同意，公司采用向社会公开发行方式 发行人民币普通股（A股）41,284,070股，发行价格为每股36.35元，募集资金总额 1,500,675,944.50元，扣除承销费、保荐费、审计费、律师费、信息披露等发行费用 104,881,526.35元后，实际募集资金净额为1,395,794,418.15元。上述资金到位情况经大 信会计 ...

证券代码：688276 证券简称：百克生物 公告编号：2025-040 公司董事会于近日收到孙晚丰先生提交的辞职报告。孙晚丰先生因工作调整 申请辞去公司第六届董事会职工代表董事、副总经理职务。离任后，孙晚丰先生 仍在公司担任董事长助理职务。 关于公司职工代表董事、高级管理人员离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 长春百克生物科技股份公司（以下简称"公司"）董事会于近日收到孙晚 丰先生提交的辞职报告。孙晚丰先生因工作调整申请辞去公司第六届董事会职工 代表董事、副总经理职务。离任后，孙晚丰先生仍在公司担任董事长助理职务。 孙晚丰先生的离任不会导致公司董事会人数低于法定最低人数，不会影 响公司董事会的正常运作，也不会影响公司正常的经营发展。 一、董事、高级管理人员离任情况 （一）提前离任的基本情况 长春百克生物科技股份公司 | | | | | | | | 是否继续 在上市公 | | 是否存 在未履 | | --- | --- | --- | --- | --- | --- | --- | --- ...

长春百克生物科技股份公司 关于将部分暂时闲置募集资金以定期存款方式存放的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 长春百克生物科技股份公司（以下简称"百克生物"或"公司"）于2025 年10月23日召开第六届董事会第九次会议，审议通过了《关于将部分暂时闲置募 集资金以定期存款方式存放的议案》，同意将最高额度不超过人民币1.5亿元（含 本数）的暂时闲置募集资金以定期存款方式存放，使用期限自前次闲置募集资金 现金管理的授权到期之日起6个月内有效，即2025年10月24日至2026年4月23日。 在前述额度及期限范围内，公司可以循环滚动使用该部分闲置募集资金。公司董 事会对上述事项发表了明确同意的意见，保荐机构中信证券股份有限公司（以下 简称"保荐机构"）出具了明确同意的核查意见。上述事项在董事会审批权限范 围内，无需提交股东会审议。现将相关情况公告如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意长春百克生物科技股份公司首次公开 发行股票注册的批复》（证监许可[2021]1594号）的同意，公司采用向 ...

关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 10 月 31 日（星期五）上午 09:00-10:00 证券代码：688276 证券简称：百克生物 公告编号：2025-041 长春百克生物科技股份公司 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 24 日（星期五）至 10 月 30 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@bchtpharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 （二）会议召开地点：上证路演中心 （三）会议召开方式：上证路演中心网络互动 三、参加人员 董事长：李秀峰 董事、总经理：姜春来 董事会秘书：张喆 长春百克生物科技股份公司（以下简称"公司" ...

Group 1 - The core point of the article is the resignation of Mr. Sun Wanfeng from his positions as employee representative director and vice general manager of Baike Biotechnology due to work adjustments, while he will continue to serve as assistant to the chairman [1] - The company will complete the election of a new employee representative director as soon as possible in accordance with legal procedures [1]

Market Overview - The biopharmaceutical sector experienced a decline of 0.57% on October 22, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Wendi Pharmaceutical (688488) with a closing price of 14.77, up 4.01% [1] - Dongbao Bio (300239) at 5.78, up 2.66% [1] - Jinke (688670) at 17.03, up 2.59% [1] - Major decliners included: - Aopumai (688293) at 55.19, down 4.40% [2] - Wofu Bio (300357) at 31.63, down 3.18% [2] - Sanofi (688336) at 59.60, down 2.39% [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 192 million yuan from institutional investors, while retail investors contributed a net inflow of 53.82 million yuan [2] - Specific stock capital flows included: - Te Bao Bio (688278) with a net inflow of 19.00 million yuan from institutional investors [3] - Hualan Bio (002007) with a net inflow of 12.05 million yuan from institutional investors [3] - Aopumai (688293) with a net outflow of 4.40% from institutional investors [3]

Core Viewpoint - The announcement by the company regarding the acceptance of the new drug application for the injection of Idaglutide α by the NMPA in China marks a significant step in the management of obesity and overweight in adults, emphasizing its potential benefits in weight management and metabolic health [1][3]. Group 1: Product Details - Idaglutide α injection is a recombinant human glucagon-like peptide-1 (hGLP-1) Fc fusion protein that requires weekly administration [3]. - The drug selectively binds and activates GLP-1 receptors, leading to appetite suppression and reduced food intake, which contributes to weight loss [3]. - It also lowers blood glucose levels in a glucose-dependent manner and improves cardiovascular and metabolic indicators [3]. Group 2: Clinical Trial Results - The new drug application is primarily based on a key Phase 3 clinical trial involving overweight adults with at least one weight-related comorbidity [4]. - Results indicated that the product significantly reduced patient weight, waist circumference, blood glucose, blood pressure, and blood lipids compared to a placebo, providing cardiovascular and metabolic benefits [4]. - The safety and tolerability of the product were found to be good, with lower rates of gastrointestinal adverse events and treatment discontinuation due to adverse events [4]. - The dose escalation regimen can reach the target maintenance dose within just four weeks, making it a quick and convenient option for patients [4]. - Currently, two Phase 3 clinical trials for the product in patients with type 2 diabetes are actively progressing, potentially benefiting a larger patient population [4].

Core Viewpoint - Baike Biological has received approval from the National Medical Products Administration for its trivalent influenza virus split vaccine (BK-01 adjuvant) clinical trial [2] Group 1 - The company announced the receipt of the clinical trial approval notice on the evening of October 13 [2] - The approval is significant for the development of the trivalent influenza vaccine, indicating progress in the company's research and development efforts [2]

Group 1 - The core point of the article is that Changchun High-tech has received approval from the National Medical Products Administration for its trivalent influenza virus split vaccine, indicating a significant advancement in its pharmaceutical development [1] - As of October 13, Changchun High-tech's market capitalization is 53.9 billion yuan [2] - The revenue composition for Changchun High-tech in the first half of 2025 shows that the pharmaceutical sector accounts for 92.83%, real estate for 6.81%, and services for 0.36% [1]